This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (18)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Beth A. Handwerger, MD; Barbara A. Blodi, MD; Suresh R. Chandra, MD; Timothy W. Olsen, MD; Thomas S. Stevens, MD

Arch Ophthalmol. 2001;119:28-32.

Objective  To investigate the safety and efficacy of low-dose intravitreal tissue plasminogen activator (tPA) and an expansile gas bubble in displacing submacular hemorrhage in patients with age-related macular degeneration (ARMD).

Patients and Methods  We reviewed retrospectively the medical records of 14 consecutive patients with ARMD from 1 academic center who received low-dose intravitreal tPA (18-50 µg) and expansile gas (0.3-0.4 mL of perfluoropropane) for thrombolysis and displacement of submacular hemorrhage. After the procedure, patients maintained face-down positioning for 1 to 3 days.

Main Outcome Measures  Displacement of blood from the fovea, early and final visual acuity, and toxicity of tPA.

Results  Submacular blood was completely displaced from the fovea in 10 (71%) of the 14 patients and partially displaced in 3 (21%). In 1 patient, no displacement occurred. Early (<2 months) postoperative visual acuity improved by 2 or more lines in 8 patients (57%). With a mean follow-up of 7.7 months, 2 (15%) of 13 patients maintained 2 or more lines of improvement and 69% (9 patients) maintained preoperative visual acuity. No clinical evidence of retinal toxicity was seen at this low-dose of tPA.

Conclusions  Doses of intravitreal tPA ranging from 18 to 50 µg and an expansile gas bubble are safe and effective in displacing submacular hemorrhage in patients with ARMD. Final visual acuity was limited by the underlying presence of end-stage ARMD.

From the Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison (Drs Handwerger, Blodi, Chandra, and Stevens), and Department of Ophthalmology, University of Minnesota, Minneapolis (Dr Olsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(1):149-150.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal Injection of Fluorochrome-Conjugated Peanut Agglutinin Results in Specific and Reversible Labeling of Mammalian Cones In Vivo
Krishnamoorthy et al.
IOVS 2008;49:2643-2650.
ABSTRACT | FULL TEXT  

Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage
Oshima et al.
Br. J. Ophthalmol. 2007;91:193-198.
ABSTRACT | FULL TEXT  

A study of retinal penetration of intravitreal tenecteplase in pigs.
Kwan et al.
IOVS 2006;47:2662-2667.
ABSTRACT | FULL TEXT  

Treating Subretinal Hemorrhage With Tissue Plasminogen Activator
Hesse and Blodi
Arch Ophthalmol 2002;120:102-103.
FULL TEXT